Lorbrena (Lorlatinib) Patent Expiration, LOE Window & CMS Spending

Lorbrena (Lorlatinib) by Pfizer: FDA Orange Book core substance LOE 2038-10-04, 0 AB generics, $145.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN210868 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-10-04
Last Listed Patent or Exclusivity Date2038-10-04
Orange Book Patents (*PED Extensions)4 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$145.0M
2024 Medicare Part D Spend$116.7M
2024 Medicaid Spend$28.2M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.